Sickle cell anemia is treated with a combination of daily medications, pain management during crises, blood transfusions, and in some cases, curative therapies like stem cell transplants or gene therapy. The specific approach depends on a person’s age, symptom severity, and how well they respond to first-line treatments. Most people with sickle cell disease start with preventive medications and build a treatment plan from there.
Daily Medications to Prevent Crises
The FDA has approved three medications currently on the market for sickle cell disease. The cornerstone is hydroxyurea, approved since 1998 and prescribed to patients as young as 9 months old. Hydroxyurea works by boosting levels of fetal hemoglobin, a type of hemoglobin that newborns naturally produce. Higher fetal hemoglobin levels make red blood cells bigger, rounder, and more flexible, which means they’re less likely to twist into the rigid sickle shape that causes blockages. It’s a daily pill, and your doctor will adjust the dose over time based on regular blood count checks.
L-glutamine, approved for people ages 5 and older, is a powder mixed into drinks or soft foods like applesauce. It reduces the frequency of pain crises and hospital admissions, lowers the need for blood transfusions, and cuts the risk of acute chest syndrome, a serious lung complication.
Crizanlizumab is an IV infusion given once a month, approved for adults and children 16 and older. It works differently from the other two: instead of changing the red blood cells themselves, it prevents blood cells from sticking to blood vessel walls, which keeps blood flowing and reduces pain crises and inflammation.
A fourth drug, voxelotor, was pulled from the market in September 2024 by its manufacturer after determining its benefits did not outweigh the risks.
How Pain Crises Are Treated
A vaso-occlusive crisis, the hallmark pain episode of sickle cell disease, happens when sickled red blood cells block small blood vessels. The pain can be sudden and severe, hitting the chest, abdomen, joints, or bones. When you arrive at an emergency department during a crisis, the priority is getting pain under control quickly, typically within the first 30 minutes.
Treatment starts with IV fluids to improve blood flow and strong pain relievers delivered through an IV line. You’ll also be placed on a monitor that continuously tracks your oxygen levels. If the crisis requires a hospital stay, the pain management team may set up a patient-controlled pump that lets you deliver small doses of pain medication by pressing a button, so you get relief without waiting for a nurse each time. Anti-nausea medication and laxatives are standard additions, since opioid pain relievers commonly cause nausea and constipation.
Over-the-counter pain relievers and anti-inflammatory drugs are used alongside stronger medications to reduce the total amount of opioids needed. Hospital stays for pain crises vary, but the goal is always to break the cycle of pain, ensure adequate hydration, and get you back to your baseline.
Blood Transfusions for Serious Complications
Some people with sickle cell disease need regular blood transfusions, either as an emergency measure or on a scheduled, long-term basis. The most common reason for ongoing transfusions is stroke prevention. Children identified as high risk for stroke through screening, and anyone who has already had a stroke, are typically placed on a chronic transfusion program. The goal is to keep the percentage of sickle hemoglobin in the blood below 30%, which dramatically lowers stroke risk. For people who’ve already had a stroke, this transfusion schedule is generally indefinite.
Chronic transfusions are also used for recurrent pain crises that don’t respond well enough to medications like hydroxyurea or crizanlizumab. The trade-off is iron overload: each unit of transfused blood delivers extra iron that the body can’t easily get rid of. Doctors manage this through exchange transfusions, where some of the patient’s blood is removed before new blood is given, cutting the net iron load by roughly 85% compared to a standard transfusion. When iron still accumulates, chelation therapy (medication that binds excess iron so the body can excrete it) keeps levels in a safe range.
Preventive Care for Children
Sickle cell disease weakens the spleen early in life, leaving young children highly vulnerable to certain bacterial infections. All infants and children with the most severe forms of sickle cell disease take daily prophylactic penicillin until age 5, provided they’ve completed their pneumococcal vaccine series. This simple step has been one of the most impactful interventions in pediatric sickle cell care, preventing life-threatening infections during the years when the immune system is most compromised.
Vaccination is critical and goes beyond the standard childhood schedule. Pneumococcal vaccines are especially important, and children with sickle cell disease receive additional doses to build stronger protection against the bacteria most likely to cause them serious harm.
Stem Cell Transplants
A stem cell transplant (also called a bone marrow transplant) is currently the only widely available cure for sickle cell disease. It replaces the patient’s bone marrow with healthy donor marrow that produces normal red blood cells. The best outcomes come from a matched sibling donor, meaning a brother or sister whose tissue type closely matches the patient’s. For children under 16 who receive a matched sibling transplant, overall survival is about 95%, and roughly 93% remain disease-free long term. For patients 16 and older, those numbers drop to about 81% survival and 77% disease-free.
Not everyone is a candidate. Transplant is generally recommended for people whose disease has caused significant complications despite optimal medical therapy: those who’ve had a stroke, frequent pain crises that don’t respond to medications, or recurrent episodes of acute chest syndrome. The procedure carries real risks, including graft failure (5% to 10% of cases) and graft-versus-host disease, where the donor’s immune cells attack the recipient’s body. This complication affects roughly 13% to 15% of younger patients and up to 23% of older patients. Mortality from the procedure itself ranges from 5% to 20%, depending on age.
The biggest practical barrier is donor availability. Only about 25% of patients have a matched sibling donor. Research into using half-matched family donors and unrelated donors has expanded options, but matched sibling transplants remain the gold standard.
Gene Therapy
In December 2023, the FDA approved two gene therapies for sickle cell disease, marking a new era in treatment. Both are one-time procedures that modify the patient’s own stem cells, so there’s no need for a donor match.
Casgevy uses CRISPR gene-editing technology to cut specific sections of DNA in a patient’s stem cells. This edit reactivates fetal hemoglobin production, the same protective mechanism that hydroxyurea targets, but at a much higher and more sustained level. The modified cells are infused back into the patient, where they take root in the bone marrow and continuously produce fetal hemoglobin. In clinical trials, 29 out of 31 evaluable patients (93.5%) went at least 12 consecutive months without a severe pain crisis.
Lyfgenia takes a different approach. It uses a viral delivery system to insert a new gene into the patient’s stem cells, which then produce a modified hemoglobin that functions like normal adult hemoglobin. Red blood cells carrying this engineered hemoglobin are far less likely to sickle. In trials, 88% of patients experienced complete resolution of pain crises between 6 and 18 months after treatment.
Both therapies require intensive preparation, including chemotherapy to clear the existing bone marrow before the modified cells are infused. Recovery takes weeks to months in a specialized medical center. These treatments are expensive and currently available at a limited number of hospitals, but they represent the closest thing to a permanent fix for the disease without needing a donor.
Ongoing Screening for Organ Damage
Sickle cell disease doesn’t just cause pain crises. Over time, repeated episodes of blocked blood flow can quietly damage organs. Screening for these complications is a routine part of long-term care. Starting at age 10, yearly eye exams with a retina specialist are recommended to catch sickle cell retinopathy, a condition where abnormal blood vessel growth in the retina can lead to vision loss. When caught early, laser treatment can usually prevent further damage.
The kidneys are another common target. Sickle cells damage the tiny blood vessels in the kidneys over time, and regular urine and blood tests help detect early signs of decline. The lungs are also at risk: high blood pressure in the lung arteries (pulmonary hypertension) develops in a significant number of adults with sickle cell disease and requires its own monitoring and treatment. These screenings won’t prevent organ damage entirely, but they catch problems at a stage where intervention can slow or stop progression.